Eris Biotech

Eris Biotech is privately held, so there is no public ticker and no exchange order book. Stock typically changes hands when early investors, employees, or funds with existing positions decide to sell, often via a broker or a structured secondary. Transfers are usually subject to the company’s right of first refusal and other restrictions in the stockholders’ agreement. If you are eligible, you can post a buy request on Bubex so holders looking to exit Eris Biotech can find you.

Post a Eris Biotech deal request →

There is no official Eris Biotech share price. Private names do not print a close. Indicative levels can be inferred from the last priced round, tender offers, and reported secondaries, but those prints are not executable quotes and they often disagree with one another. Cross-check platforms and brokers; the better execution is usually the one you actually get filled at, not the headline mark.

No. Eris Biotech is not listed on NYSE, Nasdaq, or any other public exchange. Any purchase is an off-exchange transfer of existing private stock (or an interest in a vehicle that holds it), not an IPO subscription.

Nobody knows. Eris Biotech has not filed to go public, and private companies do not publish an IPO date in advance. Rumours, banker mandates, and “late 20XX” chatter are not a timetable — many names stay private, get acquired, or slip the listing by years. Until a registration statement is actually filed, treat any IPO date as unknown and use the secondary market if you need access before a listing.

Secondary access to Eris Biotech is generally limited to accredited investors and other eligible counterparties. Even then, the company or its transfer agent may need to approve the transferee. Bubex introduces buyers and sellers; it is not a broker-dealer and does not execute, custody, or settle the trade.

Existing holders — typically employees after a vesting event, early investors, or funds — may be able to sell, subject to lock-ups, ROFR, and company policy. If you hold Eris Biotech stock and want liquidity, you can post a sell offer on Bubex to find qualified buyers rather than waiting for a company-run tender.

Post a Eris Biotech sell offer →

Private-market value is not a single number. Practitioners look at the last primary round, any 409A, reported tender prices, and implied marks from secondaries. Those inputs can diverge: secondaries often trade at a discount or, less often, a premium to the last round. Bubex surfaces the latest disclosed round and any market indications we can corroborate; treat them as context, not a valuation opinion.

A funding round is a primary issuance: the company sells new shares and the post-money valuation is reset. A secondary trade is a transfer of shares already outstanding between two holders; it does not recapitalise Eris Biotech the same way. Secondary price per share can therefore sit well away from the last-round mark, which is why you should not treat the headline valuation as your entry price.